Darexaban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Darexaban
Accession Number
DB12289
Description

Darexaban has been used in trials studying the prevention and basic science of Japanese, Caucasian, Thromboembolism, Pharmacodynamics, and Pharmacokinetics, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 474.561
Monoisotopic: 474.226705462
Chemical Formula
C27H30N4O4
Synonyms
Not Available
External IDs
  • YM-150
  • YM150

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Darexaban.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Darexaban.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Darexaban.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Darexaban.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Darexaban.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Darexaban.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Darexaban.
AldesleukinThe risk or severity of bleeding can be increased when Darexaban is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Darexaban is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Darexaban is combined with Alteplase.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Product Ingredients
IngredientUNIICASInChI Key
Darexaban Maleate03RTP2436R365462-24-4WHMPMUVISXATBH-BTJKTKAUSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Aminobenzoic acids and derivatives / Benzamides / Aniline and substituted anilines / Anisoles / Benzoyl derivatives / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / 1-hydroxy-2-unsubstituted benzenoids / 1,4-diazepanes
show 8 more
Substituents
1,4-diazepane / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alkyl aryl ether / Amine / Amino acid or derivatives / Aminobenzoic acid or derivatives / Aniline or substituted anilines / Anisole / Aromatic heteromonocyclic compound
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
KF322K101S
CAS number
365462-23-3
InChI Key
IJNIQYINMSGIPS-UHFFFAOYSA-N
InChI
InChI=1S/C27H30N4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34)
IUPAC Name
N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
SMILES
COC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1

References

General References
Not Available
PubChem Compound
9912771
PubChem Substance
347828557
ChemSpider
8088422
BindingDB
50358252
ChEMBL
CHEMBL1922235
ZINC
ZINC000070647134
Wikipedia
Darexaban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionVenous Thromboembolism4
2CompletedPreventionAcute Coronary Syndromes (ACS)1
2CompletedPreventionArthroplasty, Replacement, Knee1
2CompletedPreventionAtrial Fibrillation (AF)2
2CompletedPreventionThromboembolism2
2, 3CompletedPreventionArthroplasty, Replacement, Hip / Venous Thromboembolism1
2, 3CompletedPreventionVenous Thromboembolism2
1CompletedNot AvailableHealthy Elderly Subjects / Pharmacokinetics of YM1501
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic and Pharmacokinetic Interaction1
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic Interaction2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0291 mg/mLALOGPS
logP4.03ALOGPS
logP2.96ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)8.32ChemAxon
pKa (Strongest Basic)8.95ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.14 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity140.91 m3·mol-1ChemAxon
Polarizability52.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:50 / Updated on July 10, 2020 21:43

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates